DeCode and Illumina to Co-Develop Diagnostic Tests
Posted on: Monday, 15 May 2006, 21:06 CDT
DeCode genetics and Illumina have formed an alliance under which the companies plan to co-develop and commercialize DNA-based diagnostic tests for several major diseases.
The collaboration will initially focus on developing diagnostic tests for genetic variations linked to heart attack, type 2 diabetes and breast cancer.
The alliance will employ Illumina's platform for high-multiplex single- nucleotide polymorphism (SNP) genotyping to develop tests for gene variants DeCode has previously shown to have impact on the risk of a growing number of common diseases with major public health impact.
The companies will share development costs and split the profits from sales of the diagnostics tests.
"This alliance enables us to strengthen our global leadership in using human genetics to discover and develop better medicine - accelerating our target discovery work and enabling us to generate near-term product revenue from the development of diagnostics," said Kari Stefansson, CEO of DeCode.
Source: Datamonitor
Related Articles
- Synopsys TetraMAX ATPG Cuts Test Development Schedule at Arrow Electronics
- New NI TestStand Software Reduces Test Development Time With Enhanced Programming Language Integration
- New Test Developed To Detect Melamine In Milk
- Test Developed for Abuse of New Heart Drug by Athletes
- Test developed for sports endurance drugs
- New Test Developed For Predicting Depression
- New Cystic Fibrosis Blood Test Developed
- BluePoint Energy Names Kirk M. Fowkes Director of Business Development and Alliances
- Standards for Anthrax Tests Developed
- (MCDT) McDATA and ADVA Optical Networking Complete Interoperability Testing and Announce Alliance Partnership
 |
 |
User Comments (0)
RSS Feeds